Tufts CSDD R&D Management Reports Single Issue
Managing the Transition from Nonclinical to Early Clinical Development
April 2012; Vol. 7 No. 2
Drug companies looking to increase the efficiency and productivity of their R&D pipelines are turning to a host of techniques and approaches aimed at shortening the time from nonclinical to early clinical development—with promising results—according to a panel of leaders from the research-based drug industry recently convened by the Tufts Center for the Study of Drug Development.
View Press Release Purchase single issue
Resource Management Strategies to Optimize R&D Performance
January 2012; Vol. 7 No. 1
Pharmaceutical and biopharmaceutical companies, under pressure to increase R&D productivity, are expanding their use of strategic partnerships to bring new drugs to market more quickly and at lower cost, according to a panel of leaders from the research-based drug industry recently convened by the Tufts Center for the Study of Drug Development.
View Press Release Purchase single issue
Designing and Maintaining Successful Innovation Partnerships
October 2011; Vol. 6 No. 4
Responding to strong and growing pressure to reduce development times and increase the output of new medicines, drug companies are engaging in innovative partnerships that are leading to, among other things, more molecular entities entering Phase I trials and shorter study times, according to a panel of leaders from the research-based drug industry recently convened by the Tufts Center for the Study of Drug Development.
View Press Release Purchase single issue
Management Implications of the Global Regulatory Environment
August 2011; Vol. 6 No. 3
As pharmaceutical and biopharmaceutical companies increase the number of clinical trials they conduct in emerging global markets, growing regulatory complexity is forcing them to change the way they operate, according to a panel of leaders from the research-based drug industry recently convened by the Tufts Center for the Study of Drug Development.
View Press Release Purchase single issue
Managing Global Investigative Sites for Peak Operational Efficiency
April 2011; Vol. 6 No. 2
Looking to improve the operational efficiency of clinical trials, drug developers are actively pursuing new strategies that include collaborating with investigative sites in developing protocols and educating patients about trials before they agree to participate, according to a panel of leaders from the research-based drug industry recently convened by the Tufts Center for the Study of Drug Development.
View Press Release Purchase single issue
Translational Science Expected to Play a Growing Role in Creating New Drugs
January 2011; Vol. 6 No. 1
To produce drug candidates at the pace needed to remain competitive, pharmaceutical and biotech companies increasingly are using translational science to make decisions about what targets to pursue and how to allocate resources, according to a panel of pharmaceutical and biotech industry leaders and academics recently convened by the Tufts Center for the Study of Drug Development.
View Press Release Purchase single issue
Pharma and Biotech Firms Are Rethinking Their Approach to Outsourcing
October 2010; Vol. 5 No. 4
The current business climate is challenging pharmaceutical and biotech companies to rethink their approach to outsourcing and how best to build alliances with external service providers as part of a long term drug development strategy, according to a panel of pharmaceutical and biotech industry leaders recently convened by the Tufts Center for the Study of Drug Development.
View Press Release Purchase single issue
Maintaining Portfolio Diversity to Drug Development Risk
August 2010; Vol. 5 No. 3
Drug developers need to change the way they allocate resources for new product development, lifecycle management, and business development and licensing—collectively known as portfolio management—if they are to improve drug development productivity, according to a panel of pharmaceutical and biotech industry leaders recently convened by the Tufts Center for the Study of Drug Development.
View Press Release Purchase single issue
Improving ROI and Late Stage Clinical Success Rates
April 2010; Vol. 5 No. 2
View Press Release Purchase single issue
Comparative Approaches to Capacity Forecasting
January 2010; Vol. 5 No. 1
Growing pressure within the research-based drug industry to bring new products to market faster and more efficiently is transforming clinical trial capacity planning and forecasting from an important area of concern to a critical success factor, according to a panel of pharmaceutical and biotech industry leaders recently convened by the Tufts Center for the Study of Drug Development.
View Press Release Purchase single issue
Best R&D Practices of Top Pharma/Biotech Performers
October 2009; Vol. 4 No. 4
Drug companies racing to develop new products to replace drugs coming off patent are finding that success is increasingly tied to the company’s ability to align operational goals with strategic objectives, according to a panel of pharmaceutical and biotech industry leaders.
View Press Release Purchase single issue
Moving Drug Development Outsourcing to a Higher Level
June 2009; Vol. 4 No. 3
If drug developers are to remain competitive, they must rely less on traditional outsourcing, in which external service providers offer a way to quickly staff up for specific tasks, and seek to become development partners with those same service providers, according to a panel of drug industry leaders.
View Press Release Purchase single issue
In-licensing/Out-Licensing Strategies and Practices
April 2009; Vol. 4 No. 2
Pharmaceutical firms looking to license new drug candidates from other firms will improve their chances of achieving a successful alliance if they focus on building a relationship, not just acquiring an asset.
View Press Release Purchase single issue
Change and Opportunity in the Phase I Landscape
January 2009; Vol. 4 No. 1
Under pressure to develop new medicines more quickly and at lower cost, drug sponsors are looking to answer as many questions as possible in Phase I. Developers are increasing their reliance on patient volunteers—now accounting for 38% of all human subjects in Phase I studies—who typically cost more to recruit and retain than healthy volunteers.
View Press Release Purchase single issue
Optimizing Protocol Design Strategies to Improve Clinical Research Performance
October 2008; Vol. 3 No. 4
Improved protocol design, perhaps more than any other drug development stratagem, holds the key to faster and more efficient development and improved protocol designs provide step-by-step guidance for the conduct of clinical trials, have been shown to have a pronounced effect on reducing performance burdens and costs and accelerating development cycle time.
View Press Release Purchase single issue
Leveraging Metrics and Market Factors for Portfolio Decision Making
June 2008; Vol. 3 No. 3
While the trend to outsource key elements of drug development to service providers could slow down due in part to rising operating costs worldwide, drug developers need to adopt an outsourcing strategy that optimizes their skill sets.
View Press Release Purchase single issue
Strategic Outsourcing and Global Drug Development
March 2008; Vol. 3 No. 2
The trend to outsource key elements of drug development to service providers could slow down in the future, due in part to rising operating costs worldwide. As sponsors seek higher levels of development performance and efficiency, they are poised to move from transactional outsourcing to more strategic partnerships. This report summarizes a recently convened executive roundtable on the issue.
View Press Release Purchase single issue
Operating Models for R&D Excellence
February 2008; Vol. 3 No. 1
How drug developers organize their companies affects operational and financial performance: The results of the study concluded that in order to speed the pace of new drug development, pharmaceutical and biopharmaceutical companies will not only partner with each other, but will also form strong alliances with organizations outside the drug development industry.
View Press Release Purchase single issue